The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting?

People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action

(2023) Hiddo JL Heerspink et al.   Lancet Diabetes & Endocrinology

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study

(2023) Matthew Anson et al.   DIABETOLOGIA

Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohort study

(2022) Fanny Jansson Sigfrids et al.   Lancet Diabetes & Endocrinology

A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches

(2022) Akira Mima   ADVANCES IN THERAPY

Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease

(2021) Akira Mima   ADVANCES IN THERAPY

Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review

(2021) Ana María Gómez-Perez et al.   Journal of Clinical Medicine

Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease

(2018) Akira Mima   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

(2017) Aidin Rawshani et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes

(2009) P.-H. Groop et al.   DIABETES